NKGen Biotech, Inc. Warrants
NKGNW
NKGNW was delisted on the 4th of March, 2025.
31 hedge funds and large institutions have $224K invested in NKGen Biotech, Inc. Warrants in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
3% more funds holding
Funds holding: 30 → 31 (+1)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
35% less capital invested
Capital invested by funds: $346K → $224K (-$122K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTUS
Flow Traders U.S.
New York
|
+$1.59K |
| 2 |
CAC
Cowen and Company
New York
|
+$1.56K |
| 3 |
SFA
Sequoia Financial Advisors
Akron,
Ohio
|
+$1.47K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$716 |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$595 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$5.07K |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.14K |
| 3 |
VF
Virtu Financial
New York
|
-$2K |
| 4 |
TCA
Taconic Capital Advisors
New York
|
-$6 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GF
26
Gabelli Funds
Rye,
New York
| $1.5K | – | – | – |
|
|
SFA
27
Sequoia Financial Advisors
Akron,
Ohio
| $1.37K | +$1.47K | +14,072 | New |
|
|
28
UBS Group
Zurich,
Switzerland
| $1.32K | -$4 | -34 | -0.2% |
|
|
CL
29
CSS LLC
Chicago,
Illinois
| $1.25K | – | – | – |
|
|
FTUS
30
Flow Traders U.S.
New York
| $1K | +$1.59K | +15,246 | New |
|
|
CCM
31
CAAS Capital Management
New York
| $870 | – | – | – |
|
|
VF
32
Virtu Financial
New York
| – | -$2K | -13,631 | Closed |
|
NKGNW Hedge Fund Activity: Q2 2024 in Review
31 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Warrants (NKGNW) for Q2 2024, worth a combined $224K — down 35% from $346K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new NKGNW positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Flow Traders U.S., opening a new position worth an estimated $1.59K. The largest seller was Periscope Capital, cutting an estimated $5.07K.
- 31 institutional investors held NKGen Biotech, Inc. Warrants (NKGNW) as of Q2 2024, up from 30 in Q1 2024.
- Funds reported $224K of NKGen Biotech, Inc. Warrants stock for Q2 2024, down 35% quarter-over-quarter.
- 2 funds opened new NKGen Biotech, Inc. Warrants positions in Q2 2024 and 1 closed out, a net change of +1 holder.
- The largest NKGen Biotech, Inc. Warrants buyer in Q2 2024 was Flow Traders U.S., an estimated $1.59K added.
- The largest NKGen Biotech, Inc. Warrants seller in Q2 2024 was Periscope Capital, an estimated $5.07K sold.
Based on aggregated 13F filings for Q2 2024.